Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038411 | 1.00 | MAPT (0.54) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL1538922 | 0.91 | MAPT (0.56) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL6678642 | 0.88 | MEN1 (0.49) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL20982523 | 0.85 | TSHR (0.44) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL20982813 | 0.85 | MEN1 (0.46) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL11483675 | 0.84 | MAPT (0.54) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL11962582 | 0.82 | TDP1 (0.50) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL11276316 | 0.82 | MAPT (0.47) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL11839032 | 0.81 | GSTP1 (0.52) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL11158179 | 0.79 | DTYMK (0.62) | MAPTTSHRTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-20200095206-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-03-26 | — | — | US | disclosed |
| CN-110573154-A | Compositions and methods for modulating short-chain dehydrogenase activity | 卡斯西部储备大学 | 2019-12-13 | — | — | CN | disclosed |
| WO-2018145080-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
| US-4185018-A | Process for producing benzofurazan-1-oxides | CIBA-GEIGY CORPORATION (US) | 1980-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095206-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | HPGD, GCDH, HPGDS | MAPT 3596/4885LMNA 1538/4885ALDH1A1 136/4885 |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | MAPT 4097/4885LMNA 4583/4885ALDH1A1 609/4885 |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | HPGD, GCDH, HPGDS | MAPT 3596/4885LMNA 1538/4885ALDH1A1 136/4885 |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | HPGD, GCDH, HPGDS | MAPT 3596/4885LMNA 1538/4885ALDH1A1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.